One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
In recent years, the positive results of trials for mechanical thrombectomy (MT) have brought
a new era for large artery occlusion patients, especially those beyond the time window of
intravenous thrombolysis. However, interventional procedures can cause endothelial injuries
leading to local activation of platelet aggregation and subsequent thromboembolic
complications or early re-occlusion.Tirofiban is a specific antagonist of the platelet
glycoprotein (GP) IIb/IIIa receptor, which is considered highly effective against the final
common pathway of platelet aggregation and preventing vascular reocclusion. However, there is
no consensus on if AIS patients treated with MT also benefit from intravenous tirofiban. This
study aims to evaluate the effectiveness and safety of profiles of tirofiban during MT and
provide reliable clinical evidence for the treatment of tirofiban in AIS patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai East Hospital
Collaborators:
Ningbo No. 1 Hospital Qilu Hospital of Shandong University Shanghai 6th People's Hospital